Research programme: diabetes therapy - ProsidionAlternative Names: DIVA; PSN-IV/119-1
Latest Information Update: 04 Jul 2011
At a glance
- Originator Prosidion
- Mechanism of Action CD26 antigen inhibitors; GPR119 protein agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Diabetes mellitus
Most Recent Events
- 16 Jun 2009 Preclinical trials in Diabetes mellitus in United Kingdom (PO)